Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Conflicting ESMO Data Raise Questions About Role of CDK4/6 Inhibitors in Adjuvant Breast Cancer

Premium

Adding Verzenio to hormone therapy reduced the risk of relapse by 25 percent, while the PALLAS study, testing another CDK4/6 inhibitor, failed.

Pfizer's Lobrena Yields Impressive Responses in ALK-Positive NSCLC With Brain Metastases

Premium

The data may result in another option for patients in the crowded first-line ALK-positive lung cancer market, though progression-free survival data are not yet mature.

Vectibix, Bavencio Show Activity as 'Rechallenge' Therapy Strategy in Metastatic Colorectal Cancer

Premium

Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.

Octimet Oncology Licenses MET Inhibitor to Allist Pharma for Development in China

The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.

NeoGene Raises $110M in Series A Funding

The company will use the funds to further develop its proprietary technology for identifying and isolating specific T-cell receptor genes from patients' tumor samples.

Sep 14, 2020

Seneca Therapeutics to Launch Phase I/II Study for Oncolytic Immunotherapy in Q2 2021

Sep 14, 2020

COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials

Premium

Sep 08, 2020

FDA Alerts Docs, Patients to Lack of Benefit With Tecentriq-Paclitaxel in Metastatic TNBC

Sep 08, 2020

Atara Starting Phase I Trial for Mesothelin-Directed CAR T-cell Therapy

Sep 04, 2020

Relay Therapeutics Initiates Human Study of Selective FGFR2 Inhibitor RLY-4008

Sep 03, 2020

Rain Therapeutics Closes $63M Series B Funding

Sep 02, 2020

Rain Therapeutics Garners Worldwide License to MDM2 Inhibitor Programs From Daiichi Sankyo

Sep 01, 2020

Sotio Acquires Unum Therapeutics Cell-Based Therapy Assets

Aug 31, 2020

CAR T-Cell Therapy Targeting CD30 Yields Responses, No Neurotoxicity in Hodgkin's Lymphoma

Premium

Aug 28, 2020

Freenome Maintains CRC Early Detection Timeline as New Biomarker Discovery Studies Progress

Premium

Aug 28, 2020

Treadwell Therapeutics Advances Phase I TTK Inhibitor to Breast Cancer Subpopulations

Aug 26, 2020

Oncolytics Biotech Doses First TNBC Patient in Phase II Trial of Peloreorep, Retifanlimab Combo

Aug 25, 2020

Acepodia's NK Cell Therapy Enters Human Studies in HER2 Expressing Solid Tumors

Premium

Aug 25, 2020

Bristol Myers' Idhifa Fails to Meet Phase III Survival Endpoint in Refractory AML

Aug 24, 2020

Cancer Genetics to Acquire Organoid Startup Stemonix

Aug 19, 2020

Turning Point's Repotrectinib Yields Promising Early Data in ROS1-, NTRK-Positive Cancers

Aug 18, 2020

Gilead Expands Oncology Collaboration, Makes $145M in Upfront, Equity Payments to Tango Therapeutics

Aug 17, 2020

Precigen Doses First Patient in Phase I/II Immunotherapy Trial For HPV-Associated Cancers

Aug 12, 2020

Basket Trial Data Supports Further Study of Lynparza, Imfinzi Regimen in BRCA-Mutated Breast Cancer

Premium

Aug 12, 2020

Menu

Drug Discovery & Development

Conflicting ESMO Data Raise Questions About Role of CDK4/6 Inhibitors in Adjuvant Breast Cancer

Pfizer's Lobrena Yields Impressive Responses in ALK-Positive NSCLC With Brain Metastases

Vectibix, Bavencio Show Activity as 'Rechallenge' Therapy Strategy in Metastatic Colorectal Cancer

Octimet Oncology Licenses MET Inhibitor to Allist Pharma for Development in China

NeoGene Raises $110M in Series A Funding

Seneca Therapeutics to Launch Phase I/II Study for Oncolytic Immunotherapy in Q2 2021

COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials

FDA Alerts Docs, Patients to Lack of Benefit With Tecentriq-Paclitaxel in Metastatic TNBC

Atara Starting Phase I Trial for Mesothelin-Directed CAR T-cell Therapy

Relay Therapeutics Initiates Human Study of Selective FGFR2 Inhibitor RLY-4008

Rain Therapeutics Closes $63M Series B Funding

Rain Therapeutics Garners Worldwide License to MDM2 Inhibitor Programs From Daiichi Sankyo

Sotio Acquires Unum Therapeutics Cell-Based Therapy Assets

CAR T-Cell Therapy Targeting CD30 Yields Responses, No Neurotoxicity in Hodgkin's Lymphoma

Freenome Maintains CRC Early Detection Timeline as New Biomarker Discovery Studies Progress

Treadwell Therapeutics Advances Phase I TTK Inhibitor to Breast Cancer Subpopulations

Oncolytics Biotech Doses First TNBC Patient in Phase II Trial of Peloreorep, Retifanlimab Combo

Acepodia's NK Cell Therapy Enters Human Studies in HER2 Expressing Solid Tumors

Bristol Myers' Idhifa Fails to Meet Phase III Survival Endpoint in Refractory AML

Cancer Genetics to Acquire Organoid Startup Stemonix

Turning Point's Repotrectinib Yields Promising Early Data in ROS1-, NTRK-Positive Cancers

Gilead Expands Oncology Collaboration, Makes $145M in Upfront, Equity Payments to Tango Therapeutics

Precigen Doses First Patient in Phase I/II Immunotherapy Trial For HPV-Associated Cancers

Basket Trial Data Supports Further Study of Lynparza, Imfinzi Regimen in BRCA-Mutated Breast Cancer

KAHR Medical to Initiate Trial of Dual-Signaling Protein in Patients With Advanced Solid Tumors

Breaking News

Illumina to Acquire Grail for $8B in Cash and Stock

Siemens Healthineers, Novartis Ink Deal to Develop Assays With Initial Focus on MS Therapeutics

Lynparza Maintenance Treatment in BRCA-Mutated Ovarian Cancer Shows Long-Term Benefit

BMS's Opdivo, Yervoy Plus Chemo Gets Positive CHMP Opinion in NSCLC Regardless of PD-L1 Status

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

Ashion Analytics Partners With Elevation Oncology to Test Patients for Seribantumab Trial Enrollment

What's Popular?

Vectibix, Bavencio Show Activity as 'Rechallenge' Therapy Strategy in Metastatic Colorectal Cancer

Pfizer's Lobrena Yields Impressive Responses in ALK-Positive NSCLC With Brain Metastases

Conflicting ESMO Data Raise Questions About Role of CDK4/6 Inhibitors in Adjuvant Breast Cancer

COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials

Octimet Oncology Licenses MET Inhibitor to Allist Pharma for Development in China